Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

NCT03836209 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

181

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Gilteritinib
DRUG: Midostaurin
DRUG: Daunorubicin
DRUG: Cytarabine

Sponsor

PrECOG, LLC.

Collaborators

[object Object]